Medical genetics in developing countries

Annual Review of Genomics and Human Genetics

Volumn 5, Issue , 2004, Pages 219-265

  Christianson, Arnold ^a   Modell, Bernadette ^b  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Congenital disorders; Epidemiology; Medical genetic services

Indexed keywords

BETA GLUCOSIDASE; FOLIC ACID; MISOPROSTOL; MULTIVITAMIN; PHENYTOIN; RECOMBINANT ENZYME; THALIDOMIDE;

CLINICAL TRIAL; CONGENITAL DISORDER; CONGENITAL MALFORMATION; CONSANGUINEOUS MARRIAGE; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DNA STRUCTURE; GAUCHER DISEASE; GENETIC SCREENING; GENETIC SERVICE; HEALTH CARE; HUMAN; LOWEST INCOME GROUP; MEDICAL GENETICS; NEURAL TUBE DEFECT; PRENATAL DIAGNOSIS; PUBLIC HEALTH; REVIEW; TERATOGENICITY; WORLD HEALTH ORGANIZATION;

ABNORMALITIES; CHILD; DEVELOPING COUNTRIES; ETHICS, MEDICAL; GENETIC DISEASES, INBORN; GENETICS, MEDICAL; HUMANS; INFANT; INFANT MORTALITY; RISK FACTORS; SOCIAL JUSTICE;

EID: 5044221020     PISSN: 15278204     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.genom.5.061903.175935     Document Type: Review

References (134)

1. Ahmed S, Saleem M, Modell B, Petrou M. 2002. Screening extended families for genetic haemoglobin disorders in Pakistan. N. Engl. J. Med. 347:1162-68
2. Akinyanju OO. 1989. A profile of sickle cell disease in Nigeria. Ann. NY Acad. Sci. 565:126-36
3. Akinyanju OO. 1999. Initiation of prenatal diagnosis of sickle cell disorder in Africa. Prenat. Diagn. 19:299-304
4. Alwan A, Modell B. 1997. Community control of genetic and congenital disorders. East. Mediterr. Reg. Off. Tech. Publ. Ser. 24. WHO Reg. Off. East. Mediterr. Alexandria, Egypt
5. Alwan A, Modell B. 2003. Recommendations for introducing genetic services in developing countries. Nat. Rev. Genet. 4:61-67
6. Angastiniotis M, Modell B. 1998. Global epidemiology of hemoglobin disorders. Ann. NY Acad. Sci. 850:251-69
7. Angastiniotis M, Modell B, Englezos P, Boulyjenkov V. 1995. Prevention and control of haemoglobinopathies. Bull. WHO 73:375-86
8. Baird PA, Anderson TW, Newcombe HB, Lowry RB. 1988. Genetic disorders in children and young adults: a population study. Am. J. Hum. Genet. 42:677-93
9. Baird PA, Sadovnick AD. 1988. Life expectancy in Down syndrome adults. Lancet 2:1354-56
10. Behrman R, Vaughan VC III, eds. 1983 (2003). Nelson Textbook of Pediatrics. Philadelphia: Saunders. 12th ed.
11. Bittles AH. 1990. Consanguineous marriage: current global incidence and its relevance to demographic research. Res. Rep. 90-186. Popul. Stud. Cent., Univ. Mich. http://www.consang.net
12. Bittles AH, Neel JA. 1994. The costs of human inbreeding and their implications for variations at the DNA level. Nat. Genet. 8:117-21
13. Black RE, Morris SS, Bryce J. 2003. Where and why are 10 million children dying every year? Lancet 361:2226-34
14. Bloom BR, Trach DD. 2001. Genetics and developing countries. Br. Med. J. 322: 1006-7
15. Botto LD, Yang Q. 2000. 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuDE review. Am. J. Epidemiol. 151:862-77
16. Deleted in proof
17. Bryce J, el Arifeen S, Pariyo G, Lanata CF, Gwatkins D, et al. 2003. Reducing child mortality: Can public health deliver? Lancet 362:159-64
18. Bundey S, Aslam H. 1993. A five-year prospective study of the health of children in different ethnic groups, with particular reference to the effect of inbreeding. Eur. J. Hum. Genet. 1:206-19
19. Campbell C, Mzaidume Y. 2002. How can HIV be prevented in South Africa? A social perspective. Br. Med. J. 324:229-32
20. Cao A, Rosatelli MC. 1998. Screening and prenatal diagnosis of the haemoglobinopathies. Ballieres Clin. Haematol. 11:215-38
21. Castilla EE, Ashton-Prolla P, Barreda-Mejia E, Brunoni D, Cavalcanti DP, et al. 1996. Thalidomide, a current teratogen in South America. Teratology 54:273-77
22. Castilla EE, Rittler M, Dutra MG, Lopez-Camelo JS, Campana H, et al. 1998. Survival of children with Down syndrome in South America. ECLAMC-Downsurv Group. Latin American collaborative study of congenital malformations. Am. J. Med. Genet. 79:108-11
23. Christianson AL. 1996. Down syndrome in sub-Saharan Africa. J. Med. Genet. 33: 89-92
24. Christianson AL, Venter PA, Modiba JH, Nelson MM. 2000. Development of a primary health care clinical genetic service in rural South Africa-the northern province experience, 1990-1996. Community Genet. 3:77-84
25. Claeson M, Gillespie D, Mshinda H, Troedsson H, Victoria CG. 2003. Knowledge into action for child survival. Lancet 362:323-27
26. Crowther CA, Keirse MJ. 2000. Anti-D administration in pregnancy for preventing rhesus alloimmunisation. Cochrane Database Syst. Rev. 2:CD000020
27. Croxford J, Viljoen D. 1999. Alcohol consumption by pregnant women in the Western Cape. S. Afr. Med. J. 89:962-65
28. Cutts FT, Robertson SE, Diaz-Ortega JL, Samuel R. 1997. Control of rubella and congenital rubella syndrome (CRS) in developing countries. Part 1: Burden of disease from CRS. Bull. WHO 75:55-68
29. Czeizel A. 1998. The activities of the Hungarian centre for congenital anomaly control. World Health Stat. Q. 41:219-27
30. Czeizel A. 2000. Periconceptional care: an experiment in community genetics. Community Genet. 3:119-23
31. Czeizel A, Sankaranarayanan K. 1984. The load of genetic and partially genetic disorders in man. I. Congenital anomalies: estimates of detriment in terms of years of life lost and years of impaired life. Mutat. Res. 128:73-103
32. Czeizel AE. 1993. Prevention of congenital anomalies by periconceptional multivitamin supplementation. Br. Med. J. 306:1645-48
33. Czeizel AE, Dudas I. 1992. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N. Engl. J. Med. 327:1832-35
34. Czeizel AE, Intôdy Z, Modell M. 1993. What proportion of congenital abnormalities can be prevented? Br. Med. J. 306:499-503
35. Czeizel AE, Toth M, Rockenbauer M. 1996. Population-based case control study of folk acid supplementation during pregnancy. Teratology 53:345-51
36. Davies SC, Cronin E, Gill M, Greengross P, Hickman M, Normand C. 2000. Screening for sickle cell disease and thalassaemia: a systematic review with supplementary research. Health Technol. Assess. 4(3). http://www.hta.nhsweb.nhs. uk
37. Dept. Health. Rep. Health Soc. Subj. 2000. Folic acid and the prevention of disease: Report of committee on medical aspects of food and nutrition policy. London: Stationery Off.
38. Epping-Jordan J-A, Bengoa R, Yach D. 2003. Chronic conditions-the new health challenge. S. Afr. Med. J. 93:585-90
39. EUROCAT Rep. 8. Surveillance of congenital anomalies in Europe 1980-1999. 2002. EUROCAT Work. Group. Univ. Ulster, Newtownabbey, North. Irel.
40. Fleming AF, Storey J, Molineaux L, Iroko EA, Altai EDE. 1979. Abnormal haemoglobins in the Sudan savannah of Nigeria. 1. Prevenance of haemoglobins and relationships between sickle cell trait, malaria, and survival. Ann. Trop. Med. Parasitol. 73:161-72
41. Fraser GR. 1972. The short term reduction in birth incidence of recessive diseases as a result of genetic counselling after birth of an affected child. Hum. Hered. 22:1-6
42. Galjaard H. 1994. Genetic technology in healthcare. Int. J. Technol. Healthc. 10:527-45
43. st Century. London: R. Coll. Phys.
44. Hayes A, Costa T, Scriver C, Childs B. 1985. The effect of Mendelian disease on human health II: response to treatment. Am. J. Med. Genet. 21:243-55
45. Helander E, Mendis P, Nelson G, Goerdt A. 1989. Training in the Community for People with Disabilities. Geneva: WHO
46. Heredero L. 1992. Comprehensive national genetic program in a developing country-Cuba. Birth Defects Orig. Artic. Ser. 28:52-57
47. Hesselgrave BL. 2003. Helping to manage the high cost of rare diseases. Manag. Care Q. 11:1-6
48. Honein MA, Paulozzi LJ, Mathews TJ, Eriksen JD, Wong LY. 2001. Impact of folic acid fortification of the US food supply on the occurrence of neural tube defects. JAMA 285:2981-86
49. Hook EB. 1992. Chromosome abnormalities. Prevalence, risks and recurrence. In Prenatal Diagnosis and Screening, ed. JH Brock, CH Rodeck, MA Ferguson-Smith. pp. 351-92. London: Churchill Livingstone
50. Jenkins T. 1990. Medical genetics in South Africa. J. Med. Genet. 27:760-79
51. Jones G, Steketee RW, Black RE, Bhutta ZA, Morris SS. 2003. How many child deaths can we prevent this year? Lancet 362:65-71
52. Karnon J, Zeuner D, Brown J, Ades AE, Wonke B, Modell B. 1999. Lifetime treatment costs of beta-thalassaemia major. Clin. Lab. Haematol. 21:377-85
53. Khoury MJ, Becerra JE, Coredo JF, Erikson JD. 1989. Clinical- epidemiological assessment of pattern of birth defects associated with human teratogens: application to diabetic embryopathy. Pediatrics 84:658-65
54. Krauth C, Jalilvand N, Welte T, Busse R. 2003. Cystic fibrosis: cost of illness and considerations for the economic evaluation of potential therapies. Pharmacoeconomics 21:1001-24
55. Kromberg J. 1992. Albinism in the South African Negro: IV: attitudes and the death myth. Birth Defects: Orig. Artic. Ser. 28:159-66
56. Kromberg JGR, Castle D, Zwane EM, Jenkins T. 1989. Albinism and skin cancer in southern Africa. Clin. Genet. 36:43-52
57. Kromberg JGR, Jenkins T. 1982. Prevalence of albinism in the South African Negro. S. Afr. Med. J. 61:383-86
58. La Vecchia C, Negri E, Pelucchi C, Franceschi S. 2002. Dietary folate and colorectal cancer. Int. J. Cancer 102:545-47
59. Li DK, Daling JR, Mueller BA, Hickok DE, Fantel AG, Weiss NS. 1995. Periconceptional multivitamin use in relation to the risk of congenital urinary tract anomalies. Epidemiology 6:212-18
60. Livingstone FA. 1985. Frequencies of Hemoglobin Variants. New York/Oxford: Oxford Univ. Press
61. Luande J, Henschke CI, Mohammed N. 1985. The Tanzanian human albino skin. Natural history. Cancer 55:1823-28
62. Lund PM, Puri N, Durham-Pierre D, King RA, Brilliant MH. 1997. Oculocutaneous albinism in an isolated Tonga community in Zimbabwe. J. Med. Genet. 34:733-35
63. th ed.
64. MacKenzie JJ, Amato D, Clarke JT. 1998. Enzyme replacement therapy for Gaucher's disease: the early Canadian experience. Can. Med. Assoc. J. 159:1273-78
65. McDroy SP, Dynan KB, Lawson JT, Patterson CC, Passmore AP. 2002. Moderately elevated plasma homocysteine, methylenetetrahydrofolate reductase genotype, and risk for stroke, vascular dementia, and Alzheimer disease in Northern Ireland. Stroke 33:2351-56
66. McIntyre J, Gray G. 2002. What can we do to prevent mother to child transmission of HIV? Br. Med. J. 324:218-21
67. McKusick VA. 1975. The growth and development of human genetics as a clinical discipline. Am. J. Hum. Genet. 27:261-73
68. Modell B, Darr A. 2002. Genetic counselling and customary consanguineous marriage. Nat. Rev. Genet. 3:225-29
69. Modell B, Kuliev A. 1998. The history of community genetics: the contribution of the heaemoglobin disorders. Community Genet. 1:3-11
70. Modell B, Kuliev AM, Wagner M. 1992. Community Genetics Services in Europe. WHO Reg. Publ., Eur. Ser. No. 38. WHO Reg. Off. Eur. 8 Scherfigsvej, DK-2100, Copenhagen, Denmark
71. Moore LL, Bradlee ML, Singer MR, Rothman KJ, Milunsky A. 2003. Folate intake and the risk of neural tube defects: an estimation of dose-response. Epidemiology 14:200-5
72. Mourant AE. 1954. The Distribution of the Human Blood Groups. Oxford: Blackwell
73. MRC Vitamin Study Res. Group. 1991. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 338:131-37
74. Murdock GP. 1967. Ethnographic atlas. Pittsburgh, PA: Univ. Pittsburgh Press
75. Murray CJL, Lopez AD. 1997. Global mortality, disability, and the contribution of risk factors: global burden of disease study. Lancet 349:1436-42
76. Murray CJL, Lopez AD, eds. 1998. Health Dimensions of Sex and Reproduction: The Global Burden of Sexually Transmitted Diseases, HIV, Maternal Conditions, Perinatal Disorders and Congenital Anomalies. Boston: Harvard Sch. Public Health
77. th ed. NIH Publ. 02-2117
78. Online Mendelian Inheritance in Man, OMIM™. 2000. http://www.ncbi.nlm. nih.gov/omin/; http://www.hgmp.mrc.ac. uk/Embnetut/Omim/
79. Orioli IM, Castilla EE. 2000. Epidemiological assessment of misoprostol teratogenicity. Br. J. Obstet. Gynaecol. 107: 519-23
80. Pagan RA, Pinsky L, Beahler CC. 2001. Online medical genetic resources: a US perspective. Br. Med. J. 322:1035-37
81. Pass K, Harris K, Lorey F, Choi R, Kling S. 2000. Update: newborn screening for sickle cell disease-California, Illinois, and New York, 1998. MMWR Rep. 49(32):729-31
82. Paul N, Kavanagh L, eds. 1990. Genetic services for underserved populations. Birth Defects Orig. Artic. Ser. 26: 1-290
83. Pelser J. 1998. Knowledge and attitudes of South African women to prenatal diagnosis. MSc thesis. Univ. Pretoria. 167 pp.
84. Penchaszadeh VB. 1992. Implementing comprehensive genetic services in developing countries: Latin America. Birth Defects: Orig. Artic. Ser. 28:17-26
85. st Century, ed. MJ Khoury, W Burke, EJ Thomson, pp. 301-27. Oxford/New York: Oxford Univ. Press
86. Pyeritz RE, Tumpson JE, Bernhardt BA. 1987. The economics of clinical genetics services. I. Preview. Am. J. Hum. Genet. 41:549-58
87. Qureshi N, Gilbert P, Raeburn S. 2003. Consanguinity and genetic morbidity in a British primary care setting: a pilot study with trained linkworkers. Ann. Hum. Biol. 30:140-47
88. Ramalingaswami V. 2000. The public health imperative of permanent elimination of iodine deficiency. In Eighth World Salt Symposium, ed. RM Geertman, 1:3-11. Amsterdam: Elsievier
89. Ray JG, Meier C, Vermeulen MJ, Boss S, Wyatt PR, Cole DE. 2002. Association of neural tube defects and folic acid food fortification in Canada. Lancet 360:2047-48
90. Rodeck CH, Whittle MJ, eds. 1999. Fetal Medicine: Basic Science and Clinical Practice. London: Churchill Livingstone
91. Deleted in proof
92. Deleted in proof
93. Serjeant GR. 1992. Sickle Cell Disease. Oxford/New York/Tokyo: Oxford Univ. Press
94. Shadpour K. 1994. The Primary Health Care Experience in Iran. Tehran: UNICEF
95. Shaw GM, O'Malley CD, Wasserman CR, Tolarova MM, Lammer EJ. 1995. Maternal periconceptional use of multivitamins and reduced risk for conotruncal heart defects and limb deficiencies among offspring. Am. J. Med. Genet. 59:536-45
96. Shields DC, Kirke PN, Mills JL, Ramsbottom D, Molloy AM, et al. 1999. The "thermolabile" variant of methylenete-trahydrofolate reductase and neural tube defects: an evaluation of genetic risk and the relative importance of the genotypes of the embryo and the mother. Am. J. Hum. Genet. 64:1045-55
97. Shorvon SD, Farmer PJ. 1988. Epilepsy in developing countries: a review of epidemiological, sociocultural, and treatment aspects. Epilepsia 29(Suppl. 1):36-54
98. Stagno S, Pass RF, Dworsky ME, Henderson RE, Moore EG, et al. 1982. Congenital cytomegalovirus infection. N. Engl. J. Med. 306:945-49
99. Stevenson AC, Johnston HA, Stewart MIP, Golding DR. 1966. A report of a study of a series of consecutive births in 24 countries. Congenital Malformations. A report of a study of series of consecutive births in 24 countries. Geneva: WHO. 127 pp.
100. Stewart A, Haites N, Rose P. 2001. Online medical genetic resources: a UK perspective. Br. Med. J. 322:1037-39
101. Deleted in proof
102. The Int. Hum. Genome Mapp. Consort. 2001. A physical map of the human genome. Nature 409:934-41
103. Ubbink JB, Christianson AL, Bester ML, Van Allen MI, Venter PA, et al. 1999. Folate status, homocysteine metabolism, and methylene tetrahydrofolate reductase genotype in rural South African Blacks with a history of pregnancy complicated by neural tube defects. Metabolism 48:269-74
104. United Nations. 1999. Demographic Yearbook Series. New York: UN
105. United Nations Children's Fund. 1998. The State of the World's Children. New York: UNICEF
106. United Nations Children's Fund. 1999. The State of the World's Children. New York: UNICEF
107. United Nations Children's Fund. 2001. The State of the World's Children. New York: UNICEF
108. United Nations Children's Fund. 2003. The State of the World's Children. New York: UNICEF
109. Deleted in proof
110. Verjee ZH. 1993. Glucose 6-phosphate dehydrogenase deficiency in Africa-review. East Afr. Med. J. 70(Suppl. 4):40-47
111. Victoria CG, Wagstaff A, Schellenberg JA, Gwatkin D, Claeson M, Habicht J-P. 2003. Applying an equity lense to child health and mortality: more of the same is not enough. Lancet 362:233-41
112. Viljoen D, Craig P, Hymbaugh K, Boyle C, Blount S. 2003. Fetal alcohol syndrome-South Africa, 2001. MMWR 52:660-62
113. Viljoen D, Oosthuizen C, van der Westhuizen S. 1996. Patient attitudes to prenatal screening and termination of pregnancy at Groote Schuur Hospital: a two year prospective study. East Afr. Med. J. 73:327-29
114. Wald DS, Law M, Morris JK. 2002. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. Br. Med. J. 325:1202
115. Wald NJ, Law MR, Morris JK, Wald DS. 2001. Quantifying the effect of folic acid. Lancet 358:2069-73
116. Wald NJ, Noble J. 1999. Primary prevention of neural tube defects. See Ref. 85, pp. 283-90
117. Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, et al. 2003. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). Health Technol. Assess. 7:1-77
118. Wallace M, Hurwitz B. 1998. Preconception care: who needs it, who wants it, and how should it be provided? Br. J. Gen. Pract. 48:963-66
119. Watson JD, Crick FH. 1953. Molecular structure of nucleic acids: a structure for deoxyribose nucleic acid. Nature 4356:737-38
120. th ed.
121. The World Bank. 1999. World development indicators. http://www.worldbank. org
122. WHO. 1964. Human genetics and public health. Tech. Rep. Ser. No. 282. Geneva: WHO
123. WHO. 1983. Community control of hereditary anaemias: memorandum from a WHO meeting. 1983. Bull. WHO 61:63-80
124. WHO. 1989. Glucose-6-Phosphate Dehydrogenase Deficiency. Rep. WHO Work. Group. Bull. WHO 67:601-11
125. WHO. 1994. Guidelines for the Control of Haemoglobin Disorders. Geneva: WHO
126. WHO. 1996. Control of Hereditary Diseases. WHO Tech. Rep. Ser. 865. Geneva: WHO
127. WHO. 1998. Medical Genetic Services in Latin America. Geneva: WHO
128. WHO. 2000. Primary Health Care Approaches for Prevention and Control of Congenital and Genetic Disorders. Geneva: WHO
129. WHO. 2002. Collaboration in Medical Genetics. Geneva: WHO
130. WHO. 2002. Dr Gro Harlam Bruntland. Address to the Fifty-fifth World Health Assembly. Off. Dir.-Gen. Geneva: WHO
131. WHO. 2002. Folk acid and the prevention of neural tube defects: from research to public health practice. Rep. WHO/EURO Meet. Reg. Policy Prev. Congenit. Disord., Rome, Italy, 11-12 Nov. Geneva: WHO. In press
132. WHO Advisory Comm. Health Res. 2002. Genomics and World Health. Geneva: WHO
133. WHO Advisory Group. 1985. Community Approaches to the Control of Hereditary Diseases. Geneva: WHO
134. WHO/World Alliance for the Prevention of Birth Defects. 1999. Services for the Prevention and Management of Genetic Disorders and Birth Defects in Developing Countries. Geneva: WHO